Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 21, 2021 - Issue 4
Submit an article Journal homepage
5,896
Views
42
CrossRef citations to date
0
Altmetric
Perspective

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Brian Godmana Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden;b Division of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK;c Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa;d School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, MalaysiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6539-6972View further author information
ORCID Icon,
Andrew Hille Institute of Translational Medicine, University of Liverpool, UKView further author information
,
Steven Simoensf Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, BelgiumORCID Iconhttps://orcid.org/0000-0002-9512-2005View further author information
ORCID Icon,
Gisbert Selkeg Wissenschaftliches Institut Der AOK (WIdO), Berlin, GermanyORCID Iconhttps://orcid.org/0000-0002-9614-9875View further author information
ORCID Icon,
Iva Selke Krulichováh Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Hradec, Králové, Czech RepublicORCID Iconhttps://orcid.org/0000-0002-6815-0780View further author information
ORCID Icon,
Carolina Zampirolli Diasi Faculty of Pharmacy, Postgraduate Program in Medicines and Pharmaceutical Services, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil;j SUS Collaborating Centre for Technology Assessment and Excellence in Health (CCATES), Belo Horizonte, Minas Gerais, BrazilView further author information
,
Antony P Martink Faculty of Health and Life Sciences, Liverpool, UK;l QC Medica, Sim Balk Lane, York UKORCID Iconhttps://orcid.org/0000-0003-4383-6038View further author information
ORCID Icon,
Wija Oortwijnm Department for Health Evidence, Radboud University Medical Center, Nijmegen, The NetherlandsView further author information
,
Angela Timoneyb Division of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK;n NHS Lothian, Edinburgh, UKView further author information
,
Lars L Gustafssona Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, SwedenView further author information
,
Luka Voncinao Faculty of Health Studies, Rijeka, CroatiaORCID Iconhttps://orcid.org/0000-0002-1864-2381View further author information
ORCID Icon,
Hye-Young Kwonb Division of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK;p Division of Biology & Public Health, Mokwon University, Daejeon, KoreaView further author information
,
Jolanta Gulbinovicq Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, LithuaniaView further author information
,
Dzintars Gothamr Independent Researcher, Boston, MA, United StatesView further author information
,
Janet Wales Independent Consumer Advocate, Brunswick, Victoria, AustraliaView further author information
,
Wânia Cristina Da Silvai Faculty of Pharmacy, Postgraduate Program in Medicines and Pharmaceutical Services, Federal University of Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil;t Data and Knowledge Integration Center for Health(CIDACS), Fundação Oswaldo Cruz (FIOCRUZ)/ Salvador, Bahia, BrazilORCID Iconhttps://orcid.org/0000-0002-5108-5724View further author information
ORCID Icon,
Tomasz Bocheneku Department of Nutrition and Drug Research, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, PolandView further author information
,
Eleonora Allocativ Istituto Di Ricerche Farmacologiche ‘Mario Negri’ IRCCS, Milan, ItalyView further author information
,
Amanj Kurdib Division of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK;c Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa;w Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, IraqORCID Iconhttps://orcid.org/0000-0001-5036-1988View further author information
ORCID Icon,
Olayinka O. Ogunleyex Department of Pharmacology, Therapeutics and Toxicology, Lagos State University College of Medicine, Ikeja, Lagos, Nigeria;y Department of Medicine, Lagos State University Teaching Hospital, Ikeja, Lagos, NigeriaORCID Iconhttps://orcid.org/0000-0002-8921-1909View further author information
ORCID Icon,
Johanna C Meyerc Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South AfricaORCID Iconhttps://orcid.org/0000-0003-0462-5713View further author information
ORCID Icon,
Iris Hoxhaz Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, AlbaniaView further author information
,
Admir Malajaa University of Medicine, Tirana, AlbaniaView further author information
,
Christian Hierländerbb Department of Pharmaceutical Affairs, Federation of Social Insurances, Vienna, AustriaView further author information
,
Robert Sauermannbb Department of Pharmaceutical Affairs, Federation of Social Insurances, Vienna, AustriaView further author information
,
Wouter Hamelinckcc Statistics Department, Bruxelles, BelgiumView further author information
,
Guenka Petrovadd Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, BulgariaORCID Iconhttps://orcid.org/0000-0001-8116-5138View further author information
ORCID Icon,
Ott Laiusee State Agency of Medicines, Tartu, EstoniaView further author information
,
Irene Langnerg Wissenschaftliches Institut Der AOK (WIdO), Berlin, GermanyView further author information
,
John Yfantopoulosff School of National and Kapodistrian University of AthensAthens GreeceORCID Iconhttps://orcid.org/0000-0003-0424-6887View further author information
ORCID Icon,
Roberta Joppigg Pharmaceutical Drug Department, Azienda Sanitaria Locale of Verona, Verona, ItalyView further author information
,
Arianit Jakupihh Faculty of Pharmacy, UBT – Higher Education Institution, Prishtina, KosovoORCID Iconhttps://orcid.org/0000-0002-7719-9690View further author information
ORCID Icon,
Ieva Greiciute-Kuprijanovii Department of Pharmacy, Ministry of Health of the Republic of Lithuania, Vilnius, LithuaniaView further author information
,
Patricia Vella Bonannob Division of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UKView further author information
,
Jf (Hans) Piepenbrinkjj National Health Care Institute (ZIN), XH, Diemen, NetherlandsView further author information
,
Vincent de Valkjj National Health Care Institute (ZIN), XH, Diemen, NetherlandsView further author information
,
Magdalene Wladysiukkk HTA Consulting, Cracow, PolandView further author information
,
Vanda Marković-Pekovićll Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka, Banja Luka, Republic of Srpska, Bosnia and HerzegovinaORCID Iconhttps://orcid.org/0000-0001-8963-5720View further author information
ORCID Icon,
Ileana Mardaremm Faculty of Medicine, Public Health and Management Department, “Carol Davila” University of Medicine and Pharmacy Bucharest, Bucharest, RomaniaORCID Iconhttps://orcid.org/0000-0002-4725-9808View further author information
ORCID Icon,
Jurij Fürstnn Health Insurance Institute, Ljubljana, SloveniaView further author information
,
Dominik Tomekoo Faculty of Medicine, Slovak Medical University in Bratislava, Bratislava, SlovakiaORCID Iconhttps://orcid.org/0000-0003-0838-5550View further author information
ORCID Icon,
Mercè Obach Cortadellaspp Drug Department, Catalan Health Service, Catalan Health Service, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-2756-6181View further author information
ORCID Icon,
Corinne Zarapp Drug Department, Catalan Health Service, Catalan Health Service, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-6831-2233View further author information
ORCID Icon,
Caridad Pontespp Drug Department, Catalan Health Service, Catalan Health Service, Barcelona, Spain;qq Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma De Barcelona, Barcelona, SpainORCID Iconhttps://orcid.org/0000-0002-3274-6048View further author information
ORCID Icon,
Stuart McTaggartrr Public Health Scotland, Edinburgh, UKView further author information
,
Tracey-Lea Labass Centre for Health Economics Research and Evaluation, University of Technology Sydney, Broadway, Sydney, NSWView further author information
,
Øyvind Melientt Reviews and Health Technology Assessments, Norwegian Institute of Public Health, Oslo, NorwayView further author information
,
Durhane Wong-Riegeruu Health Data Science, Institute of Population Health, Liverpool, Canadian Organization for Rare Disorders, Toronto, Ontario, CanadaView further author information
,
SeungJin Baevv College of Pharmacy, Ewha Woman’s University, Seoul, South KoreaORCID Iconhttps://orcid.org/0000-0002-8993-8884View further author information
ORCID Icon &
Ruaraidh Hillww Health Data Science, Institute of Population Health Liverpool Reviews and Implementation Group, Whelan Building, University of Liverpool, Liverpool, UKORCID Iconhttps://orcid.org/0000-0002-2801-0505View further author information
ORCID Icon show all
Pages 527-540 | Received 17 Aug 2020, Accepted 29 Jan 2021, Published online: 11 Mar 2021

Citations (42)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Che Suraya Zin, Norny Syafinaz Ab Rahman, Nor Ilyani Mohamed Nazar, Amanj Kurdi & Brian Godman. (2023) Trends in the Cost of Medicines, Consultation Fees and Clinic Visits in Malaysia’s Private Primary Healthcare System: Employer Health Insurance Coverage. Journal of Multidisciplinary Healthcare 16, pages 1683-1697.
Read now
Konstantin Tachkov, Alexandra Savova, Manoela Manova & Guenka Petrova. (2023) Tackling reimbursement challenges to fair access to medicines – introduction to the topic. Expert Review of Pharmacoeconomics & Outcomes Research 23:6, pages 597-606.
Read now
Stefano Capri, Fernando Antoñanzas & Rosella Levaggi. (2023) The impact of conventional cost-effectiveness analysis on pricing dynamics in the market of new medicines: a proposed countervailing approach. Expert Review of Pharmacoeconomics & Outcomes Research 23:4, pages 431-438.
Read now
Zhiwei Zheng, Xiaobing Song, Guodong Qiu, Siqi Xu & Hongfu Cai. (2023) Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China. Current Medical Research and Opinion 39:3, pages 433-440.
Read now
Daniel Resende Faleiros, Everton Nunes da Silva, Andreia C Santos, Brian B. Godman, Ramon Goncalves Pereira & Augusto A Guerra Junior. (2022) Adoption of new therapies in the treatment of Hepatitis: a verification of the accuracy of budget impact analysis to guide investment decisions. Expert Review of Pharmacoeconomics & Outcomes Research 22:6, pages 927-939.
Read now
Simon van der Schans, Frans De Loos, Cornelis Boersma, Maarten J. Postma & Hans Büller. (2022) A novel perspective on pharmaceutical R&D costs: opportunities for reductions. Expert Review of Pharmacoeconomics & Outcomes Research 22:2, pages 167-175.
Read now
Daniel Resende Faleiros, Juliana Alvares-Teodoro, Everton Nunes da Silva, Brian B. Godman, Ramon Gonçalves Pereira, Eli Iola Gurgel Andrade, Francisco A. de Assis Acurcio & Augusto A. Guerra Júnior. (2022) Budget impact analysis of medicines: estimated values versus real-world evidence and the implications. Expert Review of Pharmacoeconomics & Outcomes Research 22:2, pages 271-281.
Read now

Articles from other publishers (35)

Ricardo Mesquita Camelo, Mariana Michel Barbosa, Luila Clicia Moura Henriques, Antony Paul Martin, Brian Godman, Augusto Afonso Guerra Júnior, Francisco de Assis Acurcio & Juliana Alvares-Teodoro. (2023) Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective. Saudi Pharmaceutical Journal 31:12, pages 101867.
Crossref
Kristina Jenei & Daniel E Meyers. (2023) Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations. BMJ Open 13:10, pages e066378.
Crossref
Catherine Pham, Fang Niu, Thomas Delate, Gary L. BuchschacherJrJr, Yan Li, Ekim Ekinci, Kim Le & Rita L. Hui. (2023) Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer. BioDrugs.
Crossref
Catterina Ferreccio. (2023) How Did We Get Here: The Best Vaccines Ever Facing the Highest Public Hesitancy?. Vaccines 11:8, pages 1323.
Crossref
Narcyz Ghinea, Wendy Lipworth, Ian Kerridge & John R. Zalcberg. (2023) How therapeutic advances have transformed the medical landscape: a primer for clinicians. Internal Medicine Journal 53:8, pages 1306-1310.
Crossref
T. Hofmarcher, P. Szilagyiova, A. Gustafsson, T. Dolezal, P. Rutkowski, C. Baxter & E. Karamousouli. (2023) Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit. ESMO Open 8:4, pages 101593.
Crossref
Tingting Lu, Yufan Huang, Zhongjie Cai, Wangchun Lin, Xiaoxiao Chen, Ruijia Chen & Yingying Hu. (2023) The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer. Frontiers in Pharmacology 14.
Crossref
Joël Ladner, Farah Madi, Roshel Jayasundera, Joseph Saba & Etienne Audureau. (2023) Phone contacts and treatment discontinuation predict survival cancer patients in a subsidized drug access program. Journal of Comparative Effectiveness Research 12:7.
Crossref
Alexandra Beletsi, Garyfallia Stefanou & Georgia Kourlaba. (2023) Time From Marketing Authorization to Reimbursement of Medicines in Greece After the Introduction of the Health Technology Assessment Process From July 2018 to April 2022. Value in Health Regional Issues 36, pages 58-65.
Crossref
Pooyeh Graili. (2023) Conditional Funding Recommendations for Drugs in Canada: A Cross-Sectional Analysis. Applied Health Economics and Health Policy 21:4, pages 673-681.
Crossref
Fanni Ispán, Tamás Hegedüs, Marcell Csanádi & Balázs Nagy. (2023) Goals and methods of managed entry agreements – can we get what we want?. Health Policy and Technology 12:2, pages 100745.
Crossref
Silvius Negoita, Romeo Ionescu, Monica Zlati, Valentin Antohi & Alexandru Nechifor. (2023) New Regional Dynamic Cancer Model across the European Union. Cancers 15:9, pages 2545.
Crossref
Hyungmin Kim, Brian Godman, Hye-Young Kwon & Song Hee Hong. (2023) Introduction of managed entry agreements in Korea: Problem, policy, and politics. Frontiers in Pharmacology 14.
Crossref
Hye-Young Kwon & Brian Godman. (2023) Editorial: Pharmaceutical policy, impact and health outcomes. Frontiers in Pharmacology 14.
Crossref
Ntobeko Magnate Mpanza, Brian Godman, Mothobi Godfrey Keele & Moliehi Matlala. (2023) Trends in the utilization of medicines sold in the private sector post- registration in South Africa and the implications for similar countries. BMC Public Health 23:1.
Crossref
Qiyou Wu, Zhiwei Lian, Xin Wang, Hanchao Cheng, Jing Sun, Hui Yu, Gong Zhang, Fan Wu, Jian Liu & Chuanben Chen. (2023) Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China. Frontiers in Pharmacology 13.
Crossref
UnwaniahAbdull Rahim, NurAishah Che Roos, Marami Mustapa, Armania Nurdin, NursiatiMohamad Taridi & YasminAnum Mohd Yusof. (2023) Anticancer effects of gingerol, shogaol and curcumin in cervical cancer: A systematic review protocol. Advances in Human Biology 0:0, pages 0.
Crossref
Marcelien H.E. Callenbach, lldikó Ádám, Rick A. Vreman, Bertalan Németh, Zoltán Kaló & Wim G. Goettsch. (2023) Reimbursement and payment models in Central and Eastern European as well as Middle Eastern countries: A survey of their current use and future outlook. Drug Discovery Today 28:1, pages 103433.
Crossref
Saeed Mohammadpour, Samira Soleimanpour, Javad Javan-Noughabi, Nasrin Aboulhasanbeigi Gallehzan, Ali Aboutorabi, Reza Jahangiri, Rafat Bagherzadeh, Julia F. Gorman & Ali Nemati. (2022) A systemmatic literature review on indirect costs of women with breast cancer. Cost Effectiveness and Resource Allocation 20:1.
Crossref
Olayinka Ogunleye, Brian Godman, Joseph Fadare, Steward Mudenda, Adekunle Adeoti, Adesola Yinka-Ogunleye, Sunday Ogundele, Modupe Oyawole, Marione Schönfeldt, Wafaa Rashed, Ahmad Galal, Nyasha Masuka, Trust Zaranyika, Aubrey Kalungia, Oliver Malande, Dan Kibuule, Amos Massele, Ibrahim Chikowe, Felix Khuluza, Tinotenda Taruvinga, Abubakr Alfadl, Elfatih Malik, Margaret Oluka, Sylvia Opanga, Daniel Ankrah, Israel Sefah, Daniel Afriyie, Eunice Tagoe, Adefolarin Amu, Mlungisi Msibi, Ayukafangha Etando, Mobolaji Alabi, Patrick Okwen, Loveline Niba, Julius Mwita, Godfrey Rwegerera, Joyce Kgatlwane, Ammar Jairoun, Chioma Ejekam, Rooyen Mavenyengwa, Irene Murimi-Worstell, Stephen Campbell & Johanna Meyer. (2022) Coronavirus Disease 2019 (COVID-19) Pandemic across Africa: Current Status of Vaccinations and Implications for the Future. Vaccines 10:9, pages 1553.
Crossref
Eleonora Allocati, Brian Godman, Marco Gobbi, Silvio Garattini & Rita Banzi. (2022) Switching Among Biosimilars: A Review of Clinical Evidence. Frontiers in Pharmacology 13.
Crossref
Xiaoyan Liu, Yitian Lang, Qingqing Chai, Yan Lin, Yahui Liao & Yizhun Zhu. (2022) Atezolizumab plus platinum-based chemotherapy as first-line therapy for metastatic urothelial cancer: A cost-effectiveness analysis. Frontiers in Pharmacology 13.
Crossref
Anna-Maria Fontrier. (2022) Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations. Social Science & Medicine 306, pages 115119.
Crossref
Chester O. Kolek, Sylvia A. Opanga, Faith Okalebo, Alfred Birichi, Amanj Kurdi, Brian Godman & Johanna C. Meyer. (2022) Impact of Parental Knowledge and Beliefs on HPV Vaccine Hesitancy in Kenya—Findings and Implications. Vaccines 10:8, pages 1185.
Crossref
Ruijia Chen, Yalan Zhang, Kongying Lin, Defu Huang, MaoJin You, Yanjin Lai, Jinye Wang, Yingying Hu & Na Li. (2022) Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers. Frontiers in Pharmacology 13.
Crossref
Yichen Zhang, Yuxuan Wei, Huangqianyu Li, Yixuan Chen, Yiran Guo, Sheng Han, Luwen Shi & Xiaodong Guan. (2022) Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China. PharmacoEconomics 40:7, pages 715-724.
Crossref
Alice Pisana, Björn Wettermark, Amanj Kurdi, Biljana Tubic, Caridad Pontes, Corinne Zara, Eric Van Ganse, Guenka Petrova, Ileana Mardare, Jurij Fürst, Marta Roig-Izquierdo, Oyvind Melien, Patricia Vella Bonanno, Rita Banzi, Vanda Marković-Peković, Zornitsa Mitkova & Brian Godman. (2022) Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries. Frontiers in Pharmacology 13.
Crossref
Lu Li, Shilei Yang, Yanwei Chen, Li Tian, Ying He, Bin Wu & Deshi Dong. (2022) Immune Checkpoint Inhibitors Plus an Anti-VEGF Antibody as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis and Cost-Effectiveness Analysis. Frontiers in Pharmacology 13.
Crossref
Silvio Barberato-Filho, Cristiane de Cássia Bergamaschi, Brian Godman, Marcus Tolentino Silva, Fernando de Sá Del Fiol, André Oliveira Baldoni, Jorge Otávio Maia Barreto & Luciane Cruz Lopes. (2022) Editorial: New Horizons in Health-Promoting: From Methods to Implementation Science. Frontiers in Pharmacology 12.
Crossref
Ileana Mardare, Stephen M. Campbell, Johanna C. Meyer, Israel Abebrese Sefah, Amos Massele & Brian Godman. (2022) Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care. Frontiers in Pharmacology 12.
Crossref
Ryan Rodriguez, Rachel Brunner, Samantha Spencer & Dima M Qato. (2021) Time to inclusion in clinical guidance documents for non-oncological orphan drugs and biologics with expedited FDA designations: a retrospective survival analysis. BMJ Open 11:12, pages e057744.
Crossref
Andrej Janez, Tadej Battelino, Tomasz Klupa, Győző Kocsis, Miriam Kuricová, Nebojša Lalić, Anca Pantea Stoian, Martin Prázný, Dario Rahelić, Jan Šoupal, Tsvetalina Tankova & Nataliya Zelinska. (2021) Hybrid Closed-Loop Systems for the Treatment of Type 1 Diabetes: A Collaborative, Expert Group Position Statement for Clinical Use in Central and Eastern Europe. Diabetes Therapy 12:12, pages 3107-3135.
Crossref
Patricia Vella Bonanno, Vincent Cassar & Brian Godman. (2021) A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges. Frontiers in Pharmacology 12.
Crossref
Brian Godman, Joseph Fadare, Hye-Young Kwon, Carolina Zampirolli Dias, Amanj Kurdi, Isabella Piassi Dias Godói, Dan Kibuule, Iris Hoxha, Sylvia Opanga, Zikria Saleem, Tomasz Bochenek, Vanda Marković-Peković, Ileana Mardare, Aubrey C Kalungia, Stephen Campbell, Eleonora Allocati, Alice Pisana, Antony P Martin & Johanna C Meyer. (2021) Evidence-based public policy making for medicines across countries: findings and implications for the future. Journal of Comparative Effectiveness Research 10:12, pages 1019-1052.
Crossref
Brian Godman, Abiodun Egwuenu, Mainul Haque, Oliver Ombeva Malande, Natalie Schellack, Santosh Kumar, Zikria Saleem, Jacqueline Sneddon, Iris Hoxha, Salequl Islam, Julius Mwita, Renata Cristina Rezende Macedo do Nascimento, Isabella Piassi Dias Godói, Loveline Lum Niba, Adefolarin A. Amu, Joseph Acolatse, Robert Incoom, Israel Abebrese Sefah, Sylvia Opanga, Amanj Kurdi, Ibrahim Chikowe, Felix Khuluza, Dan Kibuule, Olayinka O. Ogunleye, Adesola Olalekan, Vanda Markovic-Pekovic, Johanna C. Meyer, Abubakr Alfadl, Thuy Nguyen Thi Phuong, Aubrey C. Kalungia, Stephen Campbell, Alice Pisana, Janney Wale & R. Andrew Seaton. (2021) Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. Life 11:6, pages 528.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.